[Antiteratogenic capacity of resveratrol in streptozotocin-induced diabetes in rats]. / Capacidad antiteratogénica del resveratrol en diabetes inducida por estreptozotocina en ratas.
Rev Peru Med Exp Salud Publica
; 32(3): 457-63, 2015.
Article
en Es
| MEDLINE
| ID: mdl-26580926
ABSTRACT
OBJECTIVES:
To evaluate the anti-hyperglycemic and anti-teratogenic capacity of resveratrol in streptozotocin-induced diabetic rats. MATERIAL ANDMETHODS:
Experimental study. There were three groups, of five rats each; two groups were treated with a single dose of 50 mg/Kg of streptozotocin (STZ), in citrate buffer, at the 4th day of gestation, and the third group was considered the control, and were administered with citrate buffer only. One of the two STZ induced groups was administered with 100 mg/Kg resveratrol the days 8th to 12th, when neurulation occurs. Fetuses were obtained the 19th gestational day, and were subjected to morphologic analysis; and in fetal liver the activities of scavenging enzymes catalase, superoxide dismutase and gluthathione peroxidase were measured.RESULTS:
Resveratrol can decrease the teratogenic effect of STZ-induced diabetes, and scavenging activities were beneficed by the administration of this antioxidant.CONCLUSION:
Resveratrol shown embryoprotective properties mediated by amelioration of oxidative stress produced by maternal hyperglycemia.
Texto completo:
1
Base de datos:
MEDLINE
Asunto principal:
Estilbenos
/
Antiinflamatorios no Esteroideos
/
Diabetes Mellitus Experimental
Idioma:
Es
Revista:
Rev Peru Med Exp Salud Publica
Asunto de la revista:
SAUDE PUBLICA
Año:
2015
Tipo del documento:
Article